African American patients and uninsured patients are more likely to have diminished employment participation 2 years after being cancer free than are those with no history of cancer, according to new research published in Cancer.
African American patients and uninsured patients are more likely to have diminished employment participation 2 years after being cancer free than are those with no history of cancer, according to new research published in Cancer.
A research team, led by Christine Ekenga, PhD, MPH, examined data from a longitudinal prospective cohort study of 723 white and African American women of working age who had been diagnosed with incident stage 0 to stage IIA breast cancer (n = 347) and women who had no breast cancer history (n = 376) to examine changes in quality of life over time in women diagnosed with early-stage breast cancer and their age-matched controls. This population of cancer survivors, said the authors, is one in that has an excellent prognosis for disease-free survival.
The researchers evaluated employment trajectories at 2 years of follow-up. At each interview, study participants were asked whether they were currently employed full-time, employed part-time, unemployed/unable to work, a homemaker, or retired.
The researchers found that:
Furthermore, there was a greater likelihood of emerging employment (unemployed, unable to work, or a homemaker, at the first time point, then later employed) among non-patients in the control group, but there was no such association with emerging employment among patients. Fatigue was a significant predictor of diminished employment participation in both the patient group and the control group.
The researchers noted that, while their study assessed participants’ inability to work, it did not assess the reasons why patients were unable to work, and whether employment after treatment for cancer was influenced by factors such job autonomy, schedule flexibility, physically demanding tasks, or organizational policies. Such issues are modifiable, wrote the authors, and could influence employment outcomes among these patients. Future studies should consider these factors, especially among the most vulnerable of subgroups.
“In addition to the added benefit of employer-sponsored health insurance, paid employment has the potential to mitigate the financial stresses associated with cancer,” Ekenga said in a statement. “For women with breast cancer, employment could play a significant role in post-diagnostic health. Health benefits associated with employment include an increased sense of purpose, higher self-esteem and a stronger sense of social support from others, all of which have been associated with improved quality of life.”
Reference
Ekenga CC, Pérez M, Jargenthaler JA, Jeffe DB. Early-stage breast cancer and employment participation after 2 years of follow-up: a comparison with age-matched controls. Published February 13, 2018. Cancer. doi: 10.1002/cncr.31270.
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More